BAM
KRRO icon

Belpointe Asset Management’s Korro Bio KRRO Stock Holding History

Belpointe Asset Management’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-192
Closed -$4.82K – 2084
2023
Q1 		$4.82K Sell
192
-2
-1% -$228 ﹤0.01% 3032
2022
Q4 		$37.2K Buy
+194
New +$20K ﹤0.01% 1787

Other funds holding KRRO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WPW
Waldron Private Wealth Bridgeville, Pennsylvania $2.56B AUM 17.72% 1-Year Est. Return
NSIM
North Star Investment Management Chicago, Illinois $1.65B AUM 20.56% 1-Year Est. Return

Belpointe Asset Management's KRRO Position: Q2 2023 in Review

Belpointe Asset Management sold out of Korro Bio (KRRO) in Q2 2023, closing a stake of 192 shares — an estimated $4.82K sold.

Belpointe Asset Management first reported a position in KRRO in Q4 2022 and held it in 2 quarters. The position peaked at $37.2K in Q4 2022. 41 funds tracked by Wall St. Rank hold KRRO as of Q2 2023.

  • Belpointe Asset Management reported no remaining Korro Bio position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 192 Korro Bio shares in Q2 2023, an estimated $4.82K.
  • Belpointe Asset Management first reported a position in Korro Bio in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Korro Bio position peaked at $37.2K in Q4 2022.
  • 41 funds tracked by Wall St. Rank held Korro Bio as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.